Neoadjuvant Triprizumab and Radiotherapy in Operable Patients With Stage IIA-IIIA Non-small Cell Lung Cancer
Neoadjuvant Triprizumab and Radiotherapy in Operable Patients With Stage IIA-IIIA Non-small Cell Lung Cancer
Non-small Cell Lung Cancer|Neoadjuvant Therapy|Radiotherapy|Immunotherapy
DRUG: Toripalimab|RADIATION: Conventional segmental radiotherapy|OTHER: opreation
Major pathologic response rates, Major pathological response rates assessed by independent center pathology, 42months|Event-free survival, The time from the beginning of enrollment to the occurrence of any events, including death, disease progression, change of chemotherapy regimen, change of chemotherapy, addition of other treatments, the occurrence of fatal or intolerant side effects and other events, 42months
Overall survival, Kaplan-Meier median estimates and curves will be used to describe OS survival functions, 42 months|Pathologic complete response (pCR) rates, Pathologic complete response (pCR) rate is defined as the number of randomized participants with absence of residual tumor in lung and lymph nodes as evaluated by blinded independent pathological review., 42months|Disease-free survival, Some time until the tumor recurs or die for various reasons, 42 months|Number of Participants Experiencing Adverse Events (AEs) and serious adverse events (SAEs), Adverse events are defined as any adverse medical events that occur in the participants taking the drugs and do not necessarily have a causal relationship with the treatment. AEs/SAEs were evaluated using NCI-CTCAE v5.0, 42 months
Biomarkers, PD-L1 expression of tissue specimens、TMB、WES and changes of ctDNA in peripheral blood, 42 months
Neoadjuvant Triprizumab and Radiotherapy in Operable Patients With Stage IIA-IIIA Non-small Cell Lung Cancer